Dipl.-Ing. Dr. Thomas Mohr
Ries, A., Flehberger, D., Slany, A., Pirker, C., Mader, J. C., Mohr, T., Schelch, K., Sinn, K., Mosleh, B., Hoda, M. A., Dome, B., Dolznig, H., Krupitza, G., Müllauer, L., Gerner, C., Berger, W., & Grusch, M. (2023). Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin. Journal of Experimental and Clinical Cancer Research, 42(1), [27]. https://doi.org/10.1186/s13046-022-02582-0
Moritsch, S., Moedl, B., Scharf, I., Janker, L., Zwolanek, D., Timelthaler, G., Casanova, E., Sibilia, M., Mohr, T., Kenner, L., Herndler-Brandstetter, D., Gerner, C., Mueller, M., Strobl, B., & Eferl, R. (2022). Tyk2 is a tumor suppressor in colorectal cancer. OncoImmunology, 11(1), [2127271]. https://doi.org/10.1080/2162402X.2022.2127271
Multi-Omics Readouts of Perturbation Studies are Determined by Memory Effects from Subculture
Lukas Skos (Speaker), Patricia Bortel (Contributor), Gerhard Hagn (Contributor), Andrea Bileck (Contributor), Verena Paulitschke (Contributor), Philipp Paulitschke (Contributor), Lion Gleiter (Contributor), Thomas Mohr (Contributor), Christopher Gerner (Contributor) & Samuel Matthias Meier-Menches (Contributor)
11 May 2023
Activity: Talks and presentations › Talk or oral contribution › Science to Science